Should the NHS Prescribe Magic Mushrooms for Mental Health?

The British National Health Service (NHS) faces a difficult question: should doctors be allowed to prescribe treatments containing psilocybin, the active compound in magic mushrooms, and other psychedelic drugs to treat mental illness? This debate centers on new research suggesting these substances could help conditions like depression and PTSD, but also on the potential risks and ethical concerns.

Larissa Hope believes psilocybin, taken under clinical supervision, helped her through a severe mental health crisis. At 17, she became an actress on the TV drama Skins, but the sudden fame brought up old trauma. She found traditional antidepressants ineffective, but the guided psychedelic experience was a turning point. "When I experienced it, I burst out crying," she says. "It was the first time in my life I had ever felt a sense of belonging and safety in my body." Now, nearly twenty years later, she credits the experience, alongside therapy, with helping her confront suicidal feelings.

Not everyone has a positive experience. Jules Evans, a university researcher, had a very different reaction when he first took LSD recreationally at 18. He entered what he calls a "deluded" state. "I believed that everyone was talking about me, criticising me, judging me," he recalls. "It was the most terrifying experience of my life." Evans, who now runs the Challenging Psychedelic Experiences Project, says he later suffered from social anxiety, panic attacks, and was diagnosed with post-traumatic stress disorder (PTSD).

These opposing personal stories highlight the core dilemma for doctors and regulators. On one hand, there is promise for new treatments. On the other, there is potential for serious harm.

The debate has intensified due to recent studies indicating psychedelic drugs might help treat depression, obsessive-compulsive disorder, PTSD, and some addictions. Currently, psychedelic medicine is illegal in the UK outside of approved research or clinical trials. Since 2022, however, more than twenty trials have tested these drugs for various conditions.

The results so far are mixed but promising. Many studies suggest the treatments can help, though several have unclear results. Only a few have definitively found no benefit. The UK's medicines regulator is waiting for data from one of the largest clinical trials on psilocybin, run by the biotech firm Compass Pathways, due later this year. This data will be key in deciding whether to relax restrictions for medical use.

Professor Oliver Howes, chair of the Royal College of Psychiatrists' Psychopharmacology Committee, is cautiously optimistic. He sees psychedelics as a potentially promising new treatment for NHS patients. "One of the key messages is that this is something we desperately need—more treatments and better treatments for mental health disorders," he says. He notes they may work faster than current antidepressants. However, he strongly emphasises the need for solid evidence from trials: "It's really important that we get evidence and not overhype the potential benefits."

The use of mind-altering substances is ancient, but modern research faced major hurdles. In the 1960s and 1970s, drugs like LSD became associated with social unrest and were banned. Scientific research was also heavily restricted.

This began to change in the 2010s with work by Professor David Nutt and his team at Imperial College London. Subsequent trials on depressed patients indicated psilocybin could be at least as effective as conventional antidepressants, with fewer side effects and a faster action time. "We thought rather than wait for eight weeks for antidepressants to switch off the part of the brain associated with depression, maybe psilocybin could switch it off in the space of a few minutes," Prof Nutt explains.

However, this view is not universally accepted. Prof Nutt is a respected scientist, but his statements have been controversial. In 2009, he was dismissed as chair of the government's Advisory Committee on the Misuse of Drugs after claiming the harm from horse-riding was comparable to that from ecstasy—a comment seen as inappropriate for a government adviser.

Researchers are now investigating how psychedelics might work. At University College London, neuroscientist Dr. Ravi Das is studying whether a short-acting psychedelic called DMT can help break the learned associations in the brain that drive addiction. "Every time someone drinks, a bit like Pavlov's dog, you're learning to associate things in the environment with the rewarding effect of alcohol," he says. "We've been focusing on whether certain drugs, such as psychedelics, can break down those associations."

This is early-stage research, but the aim is to eventually offer such treatments through the NHS if they prove safe and effective. "If psychedelic therapies prove to be both safe and more effective than current treatments, I would hope to see them made accessible via the NHS—rather than to just the privileged few who can afford them privately," Dr. Das states.

Currently, most psychedelics like psilocybin, LSD, and DMT are classified as having no legitimate medical use and are tightly controlled. Only ketamine sits in a different legal category and can be used medically. Dr. Das hopes positive trial results will change this classification.

Despite the promise, doctors urge significant caution. A 2024 analysis in the British Medical Journal questioned how easy it is to determine the precise effect of psychedelic drugs. Because they are often given alongside psychotherapy, it is hard to separate the drug's effect from the therapy. The analysis also warned that short-term trials might miss potential long-term harms and the risk of misuse.

Professor Howes agrees that, except for ketamine, psychedelic treatments should not become routine UK medical practice until larger, more rigorous trials provide stronger evidence. He warns of safety issues outside controlled settings: "If people take these on their own or in a backstreet clinic, then there is no guarantee... and the safety issues start becoming a major issue."

Data from the Challenging Psychedelic Experiences Project supports these concerns. It suggests over half of regular users report an intensely difficult trip, with nearly 40% rating it as one of the top five worst experiences of their life. A small percentage reported thoughts of harming themselves or others, or being impaired for more than a day.

Jules Evans argues that doctors and regulators need a fuller understanding of these adverse effects before declaring any therapies safe. "Ideally, I would love doctors and regulators to know more about these adverse effects, and how people can recover from them, before they say any of these therapies are safe," he says.

Researchers like Prof Nutt, Prof Howes, and Dr. Das believe progress is being slowed by complex regulations for conducting clinical trials. Prof Nutt calls this a "moral failing." "There are so many people suffering unnecessarily," he told the BBC. "And some of them are dying, because of the unreasonable barriers to research and treatment that we face in this country."

He believes that once proven safe and effective, these medicines must be available through the NHS to all who need them, not just through private care. Prof Howes shares this view on the need for regulatory review to speed up research: "We desperately do need new treatments."

The government has backed plans to ease licensing for some approved clinical trials, and a working group is coordinating a cautious rollout. However, many doctors say change is moving too slowly due to bureaucratic obstacles.

Supporters hope the upcoming results from large-scale trials will lead to further relaxations, at least for research purposes. For Larissa Hope, these trials are vital. Her experience with psilocybin gave her a new perspective on life when she was suicidal. "I had a solid plan to end my life. Then suddenly, death wasn't the only way," she says. "Under psilocybin, my nervous system began, for the first time, to recognise what peace felt like." The challenge for the NHS is to balance such powerful personal testimonies with rigorous scientific evidence and concern for patient safety.